[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:familial-hypercholesterolemia-heterozygous":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":55,"states":56},"Familial hypercholesterolemia - heterozygous",7,6,[8,16,23,30,37,43,49],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07058077","A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)",[12],"Phase 2\u002FPhase 3","RECRUITING","2026-08-26T02:19:08.862440Z","2026-07-05T05:32:16.731485Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05682378","Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies",[20],"Phase 3","2026-08-26T02:15:15.642947Z","2026-05-13T02:55:06.371250Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06164730","A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease",[27],"Phase 1","2026-08-26T02:15:01.639696Z","2026-04-29T02:57:57.123951Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":35,"content_modified":36},"NCT07610278","A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia",[34],"Phase 2","2026-08-26T02:19:19.975067Z","2026-07-05T03:45:20.255841Z",{"nct_id":38,"title":39,"phases":40,"status":13,"updated_at":41,"content_modified":42},"NCT07491172","A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias",[27],"2026-08-26T02:18:15.214990Z","2026-05-05T02:43:29.073051Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT07470723","The ORIGIN-FH Study",[],"2026-08-26T02:19:18.331180Z","2026-05-05T02:43:29.364342Z",{"nct_id":50,"title":51,"phases":52,"status":53,"updated_at":47,"content_modified":54},"NCT04798430","Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction",[20],"ENROLLING_BY_INVITATION","2026-07-05T18:42:10.712995Z",[],[57,61,65],{"state":58,"count":59,"slug":60},"Florida",5,"florida",{"state":62,"count":63,"slug":64},"Ohio",4,"ohio",{"state":66,"count":67,"slug":68},"North Carolina",3,"north-carolina"]